HIV Infections Clinical Trial
Official title:
Seek, Test, Treat: An Integrated Jail-Prison-Community Model for Illinois
| Verified date | November 2019 |
| Source | University of Illinois at Chicago |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Aim-1: Evaluate opt-out versus opt-in testing for the human immunodeficiency virus (HIV) at
the Cook County jail and the Illinois Department of Corrections Northern Intake facilities.
Outcomes of interest include a) uptake of each HIV testing strategy, b) comparative
effectiveness of identifying HIV-positive cases, new cases and undisclosed cases, and c)
predictors of HIV testing.
Aim-2: Evaluate two case management strategies - "correctional case management" and
"transitional case management" - designed to improve linkage and adherence to appropriate
medical care after release from incarceration. Correctional case management is a longer-term,
more intense approach while transitional case management seeks to meet the clients' immediate
needs, link them to Ryan White case management, and then support the Ryan White case manager
in assisting these clients. Correctional case management will be compared to the standard of
care for jail detainees, and to transitional case management for persons leaving prison.
Outcomes of interest include, (a) HIV viral load and CD4 cell counts over time, (b) adherence
to medication, and (c) visits to medical providers.
Aim-3: Evaluate the impact of an incentive for HIV-positive detainees released from jail to
visit an HIV service organization where they can be linked to medical care and case
management. Outcomes of interest are essentially the same as Aim-2.
Aim-4: Assess university-based telemedicine as means to improve care of state prison inmates
living with HIV. Outcomes of interest include medication regimens, HIV viral load and CD4
cell counts, and associated health conditions.
Aim-5: Assess the uptake of partner notification and social network HIV counseling and
testing involving HIV-positive persons released from jail and prison as a means to extend the
reach of the 'seek, test, treat and retain' (STTR) model into the community.
| Status | Completed |
| Enrollment | 784 |
| Est. completion date | June 30, 2016 |
| Est. primary completion date | June 30, 2016 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - For assessing opt-out and opt-in HIV testing: all detainees in Cook County Jail and all prisoners in the Northern Intake facilities of the Illinois Department of Corrections (IDOC) - For assessing telemedicine: all HIV-positive IDOC prisoners who have received treatment for HIV. -- For assessing case management: all IDOC HIV telemedicine patients who have been released from prison and returned to Chicago in the past 60 days, and all known HIV-positive jail detainees likely to be returning the community (Chicago) within 60 days of contact with the jail's HIV clinic - For assessing a post-release incentive to visit an HIV service organization, and uptake of post-release partner notification and social network HIV testing: all former detainees participating in the case management evaluation Exclusion Criteria: - Less than 18 years old - Unable to speak English or Spanish - Incapable of providing informed consent - For jail detainees: being under extradition to a locale outside Cook County or a high likelihood of being sent to prison rather than being released to the community - For prison inmates: being under extradition to a locale outside Illinois |
| Country | Name | City | State |
|---|---|---|---|
| United States | Cermak Health Services, Cook County Jail | Chicago | Illinois |
| United States | Illinois Department of Corrections | Chicago | Illinois |
| United States | University of Illinois at Chicago, School of Public Health, COIP | Chicago | Illinois |
| Lead Sponsor | Collaborator |
|---|---|
| University of Illinois at Chicago | National Institute on Drug Abuse (NIDA) |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Change in adherence to HIV medication | baseline and 6, 12, 18 months post-baseline | ||
| Other | Change in visits to HIV medical care provider | baseline and 6, 12, 18 months post-baseline | ||
| Primary | Change in HIV viral load | baseline and 6, 12, 18 months post-baseline | ||
| Secondary | Change in CD4 cell count | baseline and 6, 12, 18 months post-baseline | ||
| Secondary | Change in community-level HIV viral load | baseline and 18 months post-baseline |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |